The challenge to identify sensitive safety biomarkers of peripheral neurotoxicity in the rat: A collaborative effort across industry and academia (IMI NeuroDeRisk project) - Archive ouverte HAL
Article Dans Une Revue Toxicology Année : 2024

The challenge to identify sensitive safety biomarkers of peripheral neurotoxicity in the rat: A collaborative effort across industry and academia (IMI NeuroDeRisk project)

Laura Micheli
  • Fonction : Auteur
David Balayssac
  • Fonction : Auteur
Jérôme Busserolles
  • Fonction : Auteur
Cristelle Dalbos
  • Fonction : Auteur
Laetitia Prival
  • Fonction : Auteur
Damien Richard
  • Fonction : Auteur
Lorenzo Di Cesare Mannelli
  • Fonction : Auteur
Alessandra Toti
  • Fonction : Auteur
Clara Ciampi
  • Fonction : Auteur
  • PersonId : 1481999
Carla Ghelardini
  • Fonction : Auteur
Katerina Vlasakova
  • Fonction : Auteur
Warren E Glaab
  • Fonction : Auteur
Yang Hu
  • Fonction : Auteur
Irena Loryan
  • Fonction : Auteur
Olivier Perrault
  • Fonction : Auteur
Mohamed Slaoui
  • Fonction : Auteur
Kuno Wuersch
  • Fonction : Auteur
Eric Johnson
  • Fonction : Auteur
Wilfried Frieauff
  • Fonction : Auteur
Kelley Penraat
  • Fonction : Auteur
Dominique Brees
  • Fonction : Auteur
Valérie Dubost
  • Fonction : Auteur
  • PersonId : 1482000
Diethilde Theil
  • Fonction : Auteur

Résumé

Peripheral nervous system (PNS) toxicity assessment in non-clinical safety studies is challenging and relies mostly on histopathological assessment. The present work aims to identify blood-based biomarkers that could detect peripheral neuropathy in rats upon exposure to neurotoxic compounds. Three anticancer agents (oxaliplatin, cisplatin, paclitaxel) and a developmental compound (NVS-1) were assessed in male rats (Wistar Han). Clinical and/or functional endpoints (i.e., electronic Von Frey, Cold Plate, and Paw Pressure tests) and blood biomarkers (i.e., neurofilament light chain (NfL), neurofilament heavy chain (NF-H), microtubule-associated protein Tau (Tau), neuron specific enolase (NSE), vascular endothelial growth factor A (VEGFA), and glial fibrillary acidic protein (GFAP)) were assessed. Drug exposure and histopathological evaluations were conducted on selected nervous tissues. Oxaliplatin, cisplatin and paclitaxel treatment resulted in a significant decrease of nociceptive thresholds. Clinical signs suggestive of PNS toxicity were observed with NVS-1. NfL was consistently increased in the NVS-1 study and correlated with moderate microscopic findings in dorsal root ganglia (DRG). Only minimal microscopic findings were observed in oxaliplatin-treated animals, whereas no treatment-related microscopic findings were observed in animals treated with cisplatin and paclitaxel. For all compounds, exposure was confirmed in the PNS tissues. Clinical and functional changes were observed with all the compounds evaluated. NfL levels in plasma proved to be the most sensitive indicator of PNS toxicities, capturing moderate nervous degeneration in DRG. A combined approach that includes both functional assessments and biomarker measurements offers a more comprehensive evaluation than histopathological analysis alone when monitoring drug-induced neurotoxicity in rat models.
Fichier principal
Vignette du fichier
1-s2.0-S0300483X24002798-main(1).pdf (10.78 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04852639 , version 1 (21-12-2024)

Licence

Identifiants

Citer

Laura Micheli, David Balayssac, Jérôme Busserolles, Cristelle Dalbos, Laetitia Prival, et al.. The challenge to identify sensitive safety biomarkers of peripheral neurotoxicity in the rat: A collaborative effort across industry and academia (IMI NeuroDeRisk project). Toxicology, 2024, 510, pp.153998. ⟨10.1016/j.tox.2024.153998⟩. ⟨hal-04852639⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More